A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers

Cyclin-dependent kinase 2 (CDK2) antagonism inhibits clustering of excessive centrosomes at mitosis, causing multipolar cell division and apoptotic death. This is called anaphase catastrophe. To establish induced anaphase catastrophe as a clinically tractable antineoplastic mechanism, induced anaphase catastrophe was explored in different aneuploid cancers after treatment with CYC065 (Cyclacel), a CDK2/9 inhibitor. Antineoplastic activity was studied in preclinical models. CYC065 treatment augmented anaphase catastrophe in diverse cancers including lymphoma, lung, colon, and pancreatic cancers, despite KRAS oncoprotein expression. Anaphase catastrophe was a broadly active antineoplastic mechanism. Reverse phase protein arrays (RPPAs) revealed that along with known CDK2/9 targets, focal adhesion kinase and Src phosphorylation that regulate metastasis were each repressed by CYC065 treatment. Intriguingly, CYC065 treatment decreased lung cancer metastases in in vivo murine models. CYC065 treatment also significantly reduced the rate of lung cancer growth in syngeneic murine and patient-derived xenograft (PDX) models independent of KRAS oncoprotein expression. Immunohistochemistry analysis of CYC065-treated lung cancer PDX models confirmed repression of proteins highlighted by RPPAs, implicating them as indicators of CYC065 antitumor response. Phospho-histone H3 staining detected anaphase catastrophe in CYC065-treated PDXs. Thus, induced anaphase catastrophe after CYC065 treatment can combat aneuploid cancers despite KRAS oncoprotein expression. These findings should guide future trials of this novel CDK2/9 inhibitor in the cancer clinic.

[1]  P. Workman,et al.  Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer , 2020, PloS one.

[2]  J. Sage,et al.  Manipulating the tumour-suppressor protein Rb in lung cancer reveals possible drug targets , 2019, Nature.

[3]  D. Feldser,et al.  RB constrains lineage fidelity and multiple stages of tumour progression and metastasis , 2019, Nature.

[4]  E. Dmitrovsky,et al.  New Cell Cycle Inhibitors Target Aneuploidy in Cancer Therapy. , 2019, Annual review of pharmacology and toxicology.

[5]  J. Roth,et al.  Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer , 2018, Journal of Translational Medicine.

[6]  E. Dmitrovsky,et al.  CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. , 2018, Cancer discovery.

[7]  G. Shapiro,et al.  Abstract CT037: Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953) , 2018, Clinical Trials.

[8]  E. Dmitrovsky,et al.  Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers , 2018, Molecular Cancer Therapeutics.

[9]  E. Dmitrovsky,et al.  Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers , 2018, Proceedings of the National Academy of Sciences.

[10]  Shreyas S. Rao,et al.  Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer , 2017, Oncotarget.

[11]  Alexandra L. Thomas,et al.  Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells , 2017, Cell cycle.

[12]  E. Dmitrovsky,et al.  Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer , 2017, Journal of the National Cancer Institute.

[13]  A. Kundaje,et al.  Molecular definition of a metastatic lung cancer state reveals a targetable CD109–Janus kinase–Stat axis , 2017, Nature Medicine.

[14]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[15]  E. Winer,et al.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.

[16]  E. Dmitrovsky,et al.  Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2 , 2016, Molecular Cancer Therapeutics.

[17]  Pei Hui,et al.  Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo , 2016, British Journal of Cancer.

[18]  P. Steeg,et al.  Targeting metastasis , 2016, Nature Reviews Cancer.

[19]  T. Mak,et al.  Targeting Mitosis in Cancer: Emerging Strategies. , 2015, Molecular cell.

[20]  E. Dmitrovsky,et al.  Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown , 2015, Molecular Cancer Therapeutics.

[21]  E. Dmitrovsky,et al.  CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. , 2015, Cancer research.

[22]  I. Wistuba,et al.  Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. , 2015, The Journal of clinical investigation.

[23]  K. Shaw,et al.  Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. , 2015, Cancer letters.

[24]  D. Cleveland,et al.  Polo-like kinase 4 inhibition: a strategy for cancer therapy? , 2014, Cancer cell.

[25]  T. Stinchcombe,et al.  KRAS mutation: should we test for it, and does it matter? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Paul Workman,et al.  Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. , 2011, Bioorganic & medicinal chemistry.

[27]  J. Chan.  A Clinical Overview of Centrosome Amplification in Human Cancers , 2011, International journal of biological sciences.

[28]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[29]  Sarat Chandarlapaty,et al.  Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients , 2011, Proceedings of the National Academy of Sciences.

[30]  E. Dmitrovsky,et al.  Anaphase Catastrophe Is a Target for Cancer Therapy , 2011, Clinical Cancer Research.

[31]  E. Dmitrovsky,et al.  Cyclin E Transgenic Mice: Discovery Tools for Lung Cancer Biology, Therapy, and Prevention , 2010, Cancer Prevention Research.

[32]  Yiling Lu,et al.  Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.

[33]  E. Dmitrovsky,et al.  MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. , 2010, The Journal of clinical investigation.

[34]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[35]  E. Dmitrovsky,et al.  Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe , 2010, Clinical Cancer Research.

[36]  Alexander Pertsemlidis,et al.  Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. , 2009, Genes & development.

[37]  F. Gergely,et al.  Centrosome function in cancer: guilty or innocent? , 2009, Trends in cell biology.

[38]  D. Pellman,et al.  Centrosomes and cancer: how cancer cells divide with too many centrosomes , 2009, Cancer and Metastasis Reviews.

[39]  D. Pellman,et al.  Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. , 2008, Genes & development.

[40]  E. Dmitrovsky,et al.  Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas , 2007, Proceedings of the National Academy of Sciences.

[41]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[42]  Ming-Sound Tsao,et al.  K-ras mutations in non-small-cell lung carcinoma: a review. , 2006, Clinical lung cancer.

[43]  J. Minna,et al.  High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. , 2006, Cancer research.

[44]  S. Gollin,et al.  Spindle Multipolarity Is Prevented by Centrosomal Clustering , 2005, Science.

[45]  Erich A. Nigg,et al.  Centrosome aberrations: cause or consequence of cancer progression? , 2002, Nature Reviews Cancer.

[46]  J. Ingle,et al.  Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Guan,et al.  Role of focal adhesion kinase in integrin signaling. , 1997, The international journal of biochemistry & cell biology.

[48]  M. Kirschner,et al.  Mitosis in a cell with multiple centrioles , 1982, The Journal of cell biology.

[49]  Yiling Lu,et al.  Assay of Rab25 function in ovarian and breast cancers. , 2005, Methods in enzymology.

[50]  A. Krämer,et al.  Centrosome replication, genomic instability and cancer , 2002, Leukemia.

[51]  B. Brinkley,et al.  Managing the centrosome numbers game: from chaos to stability in cancer cell division. , 2001, Trends in cell biology.